SUSTAINABILITY REPORT 2013-15

People Overview Self Managed Teams Mechanisation Safety Overview The Parivartan     Journey Progress on     Roadmap Incident Statistics Robust Governance Standardised     Processes Enhanced Awareness Capability Building Safety Infrastructure Safety Audits Quality Overview Top-down    Accountability Quality by Design Quality Culture     Transformation Quality Assurance Quality     Best Practices All Time Audit     Readiness Availability Overview Strategic Sourcing Risk Management Product    Rationalisation Success stories Environment Overview Roadmap Energy Management Emissions Water Waste Case Study KPIs Community Overview Focus Areas Education Livelihoods Healthcare Infrastructure     Initiatives Creating Change     Makers Productivity Overview Productivity Streams Case Study PACE Update Initiatives Engineering Excellence Overview Digitisation Automation Mechanisation Lean Manufacturing Capital Equipment Strategy Predictive Maintenance Continuous Improvement Overview Continuous     Improvement     at Work Best Practices Annexures GRI Index Acronyms Assurance Statement   Summary Report     ECONOMIC PERFORMANCE AFFORDABLE & INNOVATIVE MEDICINE Overview    |    AIM Timelines    |    Global Generics    |    PSAI    |    Proprietary Products AIM Timelines Across the reporting period, we continued to launch new products and add to our burgeoning portfolio of affordable and innovative medicine. We also continued to evolve our existing relationships and forge new relationships to accelerate the cause.   2013 April   June Zoledronic Acid injection (5 mg/100 ml), a bioequivalent generic version of Reclast®, is used to prevent skeletal fractures in patients with cancers such as multiple myeloma and prostate cancer, as well as for treating osteoporosis. It can also be used to treat hypercalcemia of malignancy and can be helpful for treating pain from bone metastases.   Lamotrigine extended release tablets (25 mg, 50 mg, 100 mg, 200 mg and 300 mg), are a therapeutic equivalent generic version of Lamictal® XR (Lamotrigine). Lamictal® XR is an anticonvulsant drug used in the treatment of epilepsy and bipolar disorders. We mutually agreed with Fujifilm Corporation to terminate the Memorandum of Understanding, which had provided for the parties to enter into an exclusive partnership in the generic drugs business for the Japanese market and to establish a joint venture in Japan. As Fujifilm realigns its long-term growth strategy for the pharmaceutical business, both companies also mutually agreed to continue to explore partnership / alliance opportunities in other pharmaceutical businesses, such as active pharmaceutical ingredient development & manufacturing, contract research & development and manufacturing, and the development & marketing of super-generics. July Decitabine injection (50 mg), a therapeutic equivalent generic version of Dacogen® (Decitabine for injection), which is beneficial in the treatment of myelodysplastic syndromes, a class of conditions where certain blood cells are dysfunctional and for Acute Myeloid Leukemia (AML). Donepezil Hydrochloride tablets (23 mg), a therapeutic equivalent generic version of Aricept® (23 mg) which is used in the palliative treatment of Alzheimer's disease.   August   September Divalproex sodium extended release tablets (250 mg and 500 mg), a therapeutic equivalent generic version of Depakote® ER. Depakote® ER is used as an anticonvulsant and mood stabilising drug, primarily in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches.   Azacitidine injection (100 mg/vial), a therapeutic equivalent generic version of Vidaza®, mainly used in the treatment of Myelodysplastic Syndrome (MDS).             2014     February   March IMITREX STATdose Pen® (Sumatriptan succinate) is mainly used in the treatment of migraine headaches. We launched Sumatriptan Injection USP, Autoinjector System 6 mg/0.5 ml, for subcutaneous use, a therapeutic equivalent generic version of IMITREX STATdose Pen® (Sumatriptan succinate) 6 mg/0.5 ml.   Moxifloxacin Hydrochloride tablets (400 mg), a therapeutic equivalent generic version of Avelox®. Avelox® is mainly used for the treatment of acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, community acquired pneumonia, complicated and uncomplicated skin and skin structure infections, and complicated intra-abdominal infections. Amlodipine Besylate and Atorvastatin Calcium tablets (2.5/10 mg, 2.5/20 mg, 2.5/40 mg, 5/10 mg, 5/20 mg, 5/40 mg, 5/80 mg, 10/10 mg, 10/20 mg, 10/40 mg and 10/80 mg), a therapeutic equivalent generic version of CADUET®. CADUET® is used for the treatment of hypercholesterolemia and hypertension. April   October Eszopiclone tablets (1 mg, 2 mg and 3 mg), is a therapeutic equivalent generic version of LUNESTA® tablets C-IV. LUNESTA® is used for the treatment of insomnia. Fenofibrate capsules (USP 43 mg and 130 mg), is a therapeutic equivalent generic version of ANTARA® (Fenofibrate) capsules. ANTARA® is used for the treatment of hypercholesterolemia or mixed dyslipidemia.   Sirolimus tablets (1 mg and 2 mg), is a therapeutic equivalent generic version of RAPAMUNE® (Sirolimus) tablets. December Valganciclovir tablets (USP 450 mg), a therapeutic equivalent generic version of VALCYTE® (Valganciclovir) tablets, was introduced in the United States. We also acquired the title and rights to the Habitrol® brand (an over-the-counter nicotine replacement therapy transdermal patch) from Novartis Consumer Health Inc. and began distribution of the product in the United States. Our Pregabalin capsules, indicated for epilepsy and generalised anxiety disorder (and not indicated for neuropathic pain), were launched in Germany. Pregabalin capsules of the innovator (LYRICAR from Pfizer) are indicated for neuropathic pain, epilepsy and generalised anxiety disorder.   2015     January   February On January 18, 2015, Aurigene Discovery Technologies Limited, a wholly owned subsidiary of the parent company, entered into a collaboration, license and option agreement with Curis Inc. to discover, develop and commercialise small molecule antagonists for immuno-oncology and precision oncology targets.   Pregabalin capsules indicated for epilepsy and generalised anxiety disorder (and not indicated for neuropathic pain) were launched in the United Kingdom also.